A case series of imatinib-induced generalized hypopigmentation and progression of existing acquired dermal melanocytosis

A case series of imatinib-induced generalized hypopigmentation and progression of existing acquired dermal melanocytosis

Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of oncological conditions, including chronic myeloid leukemia and gastrointestinal stromal tumors. The most frequent dermatological side effect reported is pigmentary abnormalities. We report a case series of three Asian Chinese...

Full description

Bibliographic Details
Main Authors: Wai Leong Kok, Qiping Chen, Siong See Joyce Lee, Sze Hon Chua, See Ket Ng
Format: Article
Language:English
Published: Taylor & Francis Group 2017-11-01
Series:Journal of Dermatological Treatment
Subjects:
imatinib
hypopigmentation
dermal melanocytosis
hori’s nevus
Online Access:http://dx.doi.org/10.1080/09546634.2017.1328099

Internet

http://dx.doi.org/10.1080/09546634.2017.1328099

Similar Items